Analysts Conflicted on These Healthcare Names: Xenon (XENE), Idexx Laboratories (IDXX) and Warby Parker (WRBY)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Xenon (XENE – Research Report), Idexx Laboratories (IDXX – Research Report) and Warby Parker (WRBY – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Xenon (XENE)
Cantor Fitzgerald analyst Joshua Schimmer maintained a Buy rating on Xenon yesterday and set a price target of $55.00. The company’s shares closed last Friday at $43.31.
According to TipRanks.com, Schimmer is a 5-star analyst with an average return of
Currently, the analyst consensus on Xenon is a Strong Buy with an average price target of $56.18, which is a 23.7% upside from current levels. In a report issued on February 23, Wolfe Research also initiated coverage with a Buy rating on the stock with a $60.00 price target.
See today’s best-performing stocks on TipRanks >>
Idexx Laboratories (IDXX)
In a report released today, Jonathan Block from Stifel Nicolaus maintained a Buy rating on Idexx Laboratories, with a price target of $775.00. The company’s shares closed last Friday at $660.84.
According to TipRanks.com, Block is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Idexx Laboratories with a $778.57 average price target.
Warby Parker (WRBY)
In a report released today, Matt Koranda from Roth MKM maintained a Hold rating on Warby Parker, with a price target of $24.00. The company’s shares closed last Friday at $25.90, close to its 52-week high of $28.68.
According to TipRanks.com, Koranda is a 1-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Warby Parker with a $29.44 average price target, representing a 17.7% upside. In a report released today, UBS also maintained a Hold rating on the stock with a $25.00 price target.
